The strongly positive expression rate of SERPIND1 was significantly higher in FIGO stage III–IV epithelial ovarian cancers than in stage I–II epithelial ovarian cancers (85.1% vs. 43.5%, P < 0.01). Here, SERPIND1 is linked to ovarian carcinoma.